CWChengde Wu

Chengde Wu

*This is an algorithmically generated author record based on publicly available information.

Chengde Wu has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • George W. Holland

    3 shared publications
  • Natalie Blok

    3 shared publications
  • Timothy P. Kogan

    Texas Biotechnology Corporation, 7000 Fannin, Suite 1920, Houston, Texas 77030

    3 shared publications
  • Andree R. Bourgoyne

    Departments of Chemistry, Pharmacology, and Preclinical Toxicology, Texas Biotechnology Corporation, 7000 Fannin, Suite 1920, Houston, Texas 77030

    2 shared publications
  • B. Raju

    Texas Biotechnology Corporation, 7000 Fannin, Suite 1920, Houston, Texas 77030

    2 shared publications
  • E. Radford Decker

    Departments of Chemistry, Pharmacology, and Preclinical Toxicology, Texas Biotechnology Corporation, 7000 Fannin, Suite 1920, Houston, Texas 77030

    2 shared publications

Latest Publications

    • 1 March 2003
      • Vol. 6  (3) , 232-9

    Recently discovered sulfonamide-, acyl sulfonamide- and carboxylic acid-based endothelin antagonists.

    by Chengde Wu, George W Holland, Tommy A Brock, Richard A F Dixon

    Endothelins (ET-1, 2 and 3) are 21-residue peptides with two disulfide bridges and a highly conserved carboxy terminal. ET-1, the most significant isoform, is a potent vasoconstrictor and mitogen that exerts its biological effects through binding to its two G protein-coupled receptors: ET(A) and ET(B). ET(A) receptors are expressed on vascular smooth muscle cells and mediate vasoconstrictive and proliferative responses to ET-1. ET(B) receptors are mainly located on endothelial cells where they clear ET-1 from circulation and mediate vasodilation via the release of nitric oxide. ET-1 has been associated with a variety of serious diseases such as pulmonary hypertension, heart failure, prostate cancer and renal dysfunction.

  • Acyl Substitution at the Ortho Position of Anilides Enhances Oral Bioavailability of Thiophene Sulfonamides: TBC3214, an ETA Selective Endothelin Antagonist

    by Chengde Wu, E. Radford Decker, Natalie Blok, Jian Li, Andree R. Bourgoyne, Huong Bui, Karin M. Keller, Vippra Knowles, Wen Li, Fiona D. Stavros, et al.

    Sitaxsentan (3, TBC11251) (Wu et al. J. Med. Chem. 1997, 40, 1690) is an orally active ETA selective endothelin antagonist that attenuates pulmonary vascular hypertension and cardiac hypertrophy in rats (Tilton et al. Pulm. Pharmacol. Ther. 2000, 13, 87). It has demonstrated efficacy in a phase II clinical trial for congestive heart failure (Givertz et al. Circulation 2000, 101, 2922). During the discovery of 3, we observed several structure−oral bioavailability relationships. To investigate whether there is any generality in these trends, we synthesized some similar pairs of compounds in the latest series (Wu et al. J. Med. Chem. 1999, 42, 4485) and evaluated their oral properties. In both series, an acyl group at the 2-position of the anilide of these thiophene sulfonamides improved oral bioavailability. As a result of this exercise, TBC3214 (17) was identified as a sitaxsentan follow-on candidate. It is very potent (IC50 for ETA = 40 pM) and highly selective for ETA vs ETB receptors (400 000-fold), with a half-life of >4 h and oral bioavailability of 25% in rats, 42% in cats, and 70% in dogs.


  • Nonpeptide endothelin antagonists in clinical development

    by C. Wu, E.R. Decker, G.W. Holland, P.M. Brown, F.D. Stavros, T.A. Brock, R.A. Dixon

    Endothelins (ET-1, ET-2 and ET-3) are 21-amino-acid peptides with two disulfide bonds that belong to the sarafotoxin family. ET-1, ET-2 and ET-3 are produced endogenously from preproendothelin to give big endothelins, which are cleaved by endothelin-converting enzyme (ECE) to yield the active protein. Endothelin has been shown to play important physiological and pathological roles by interacting with its G-protein-coupled receptors. There are two cloned ET receptors: the ET(A) receptor, which is selective for ET-1, and the ET(B) receptor, which binds ET-1, ET-2 and ET-3 with similar affinities. Since the discovery of endothelin, and especially since the availability of peptide ET antagonists such as BQ-123 and BQ-788, and nonpeptide compounds such as bosentan, considerable effort has been spent on better understanding the role of endothelin and its receptor antagonists. As a result, endothelin has been implicated in a variety of serious diseases, such as congestive heart failure, hypertension, pulmonary hypertension and prostate cancer. Research in pharmaceutical and biotechnology laboratories has generated many endothelin antagonists with either sulfonamide or triaryl carboxylic acid scaffolds, and a number of ET(A)-selective or nonselective ET(A)/ET(B) endothelin antagonists have entered clinical trials. This article will review the small-molecule ET(A)-selective and nonselective ET(A)/ET(B) antagonists that are under clinical evaluation, and highlight a member of this group of compounds, sitaxsentan. A summary of the medicinal chemistry that led to the identification of sitaxsentan will be presented, followed by selected animal and human clinical trial data. (c) 2001 Prous Science. All rights reserved.


  • Recent discovery and development of endothelin receptor antagonists

    by Chengde Wu

    Endothelin (ET) receptor antagonists, in particular ETA selective or ETA/ETB balanced antagonists, represent a new therapeutic area for serious diseases such as congestive heart failure (CHF) and pulmonary hypertension. Endothelin antagonists have profound effects on the pulmonary vasculature and the right heart whereas ACE inhibitors primarily affect the peripheral vessel and the left heart. Therefore, combination of endothelin antagonists and ACE inhibitors may be particularly useful in chronic heart failure. Pulmonary hypertension represents another unmet medical need where endothelin antagonists, especially orally-active compounds, show great promise. The importance of this field is evidenced by the number of compounds in clinical trials and by the number of patents filed in recent years. Between January 1997 and April 2000, there are 139 endothelin patents of which 128 are concerned with endothelin receptor antagonists and 11 with endothelin converting enzyme inhibitors. Of the 128 patents, 93 are ab...


  • Endothelin Antagonists: Substituted Mesitylcarboxamides with High Potency and Selectivity for ETA Receptors

    by Chengde Wu, E. Radford Decker, Natalie Blok, Huong Bui, Qi Chen, B. Raju, Andree R. Bourgoyne, Vippra Knowles, Ronald J. Biediger, Robert V. Market, et al.

    We have previously disclosed the discovery of 2,4-disubstituted anilinothiophenesulfonamides with potent ETA-selective endothelin receptor antagonism and the subsequent identification of sitaxsentan (TBC11251, 1) as a clinical development compound (Wu et al. J. Med. Chem.1997, 40, 1682 and 1690). The orally active 1 has demonstrated efficacy in a phase II clinical trial of congestive heart failure (Givertz et al. Circulation1998, 98, Abstr. #3044) and was active in rat models of myocardial infarction (Podesser et al. Circulation1998, 98, Abstr. #2896) and acute hypoxia-induced pulmonary hypertension (Chen et al. FASEB J.1996, 10 (3), A104). We now report that an additional substituent at the 6-position of the anilino ring further increases the potency of this series of compounds. It was also found that a wide range of functionalities at the 3-position of the 2,4,6-trisubstituted ring increased ETA selectivity by ∼10-fold while maintaining in vitro potency, therefore rendering the compounds amenable to fine-tuning of pharmacological and toxicological profiles with enhanced selectivity. The optimal compound in this series was found to be TBC2576 (7u), which has ∼10-fold higher ETA binding affinity than 1, high ETA/ETB selectivity, and a serum half-life of 7.3 h in rats, as well as in vivo activity.


  • A Highly Practical Route to 7-Hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one fromp-Anisidine

    by Chengde Wu, Ronald J. Biediger, Timothy P. Kogan

    The title compound was accessed via a Friedel-Crafts reaction on anisidine, followed by cyclization, N-methylation and O-demethylation. NO column chromatography was required in the process.


  • A Facile Synthesis of 5-Amino-3-trifluoromethyl-4-methoxycarbonylisoxazole

    by Chengde Wu∗

    The title compound was synthesized in 3 steps from readily available cyanoacetate and TFAA. The ester group allowed access to other functionalized isoxazole derivatives.


  • Discovery of TBC11251, a Potent, Long Acting, Orally Active Endothelin Receptor-A Selective Antagonist

    by Chengde Wu, Ming F. Chan, Fiona Stavros, B. Raju, Ilya Okun, Seymour Mong, Karin M. Keller, Tommy Brock, Timothy P. Kogan, Richard A. F. Dixon

    Previously we reported the discovery of amidothiophenesulfonamides as endothelin receptor-A antagonists with high potency and selectivity. Replacement of an amide group in this class of compounds with an acetyl group maintained the in vitro binding affinity and in vivo activity while providing a compound with oral bioavailability and longer duration of action. The optimal compound discovered during these studies, 15q (TBC11251), binds competitively to human ETA receptors with a Ki of 0.43 +/- 0.03 nM and an IC50 of 1.4 nM (IC50 for ETB = 9800 nM). This compound inhibits ET-1-induced stimulation of phosphoinositide turnover with a Ki of 0.686 nM and a pA2 of 8.0. The compound has a serum half-life in the rat and the dog of 6-7 h and 60-100% oral bioavailability. This compound is one of the most selective ETA antagonists reported and therefore is suitable for additional pharmacological and clinical investigation of the role of ETA receptors in diseases.